JP2006500384A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006500384A5 JP2006500384A5 JP2004531948A JP2004531948A JP2006500384A5 JP 2006500384 A5 JP2006500384 A5 JP 2006500384A5 JP 2004531948 A JP2004531948 A JP 2004531948A JP 2004531948 A JP2004531948 A JP 2004531948A JP 2006500384 A5 JP2006500384 A5 JP 2006500384A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- compound
- compound according
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 51
- 229910052736 halogen Inorganic materials 0.000 claims 37
- 150000002367 halogens Chemical class 0.000 claims 37
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 229910052799 carbon Inorganic materials 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 238000000034 method Methods 0.000 claims 10
- -1 —OC 2 -C 5 alkenyl Chemical group 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 201000001320 Atherosclerosis Diseases 0.000 claims 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims 4
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 4
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 4
- 108090001061 Insulin Proteins 0.000 claims 4
- 206010022489 Insulin Resistance Diseases 0.000 claims 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 4
- 102000002072 Non-Receptor Type 1 Protein Tyrosine Phosphatase Human genes 0.000 claims 4
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 claims 4
- 102000023984 PPAR alpha Human genes 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 4
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 4
- 229940125396 insulin Drugs 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 4
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 201000001421 hyperglycemia Diseases 0.000 claims 3
- 230000002608 insulinlike Effects 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 2
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 claims 2
- 208000004611 Abdominal Obesity Diseases 0.000 claims 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 2
- 229940123208 Biguanide Drugs 0.000 claims 2
- 206010065941 Central obesity Diseases 0.000 claims 2
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 2
- 229940122904 Glucagon receptor antagonist Drugs 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 229940110346 PPAR gamma partial agonist Drugs 0.000 claims 2
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 claims 2
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 2
- 102100040918 Pro-glucagon Human genes 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 claims 2
- 108010054082 Sterol O-acyltransferase Proteins 0.000 claims 2
- 229940100389 Sulfonylurea Drugs 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 2
- 239000003098 androgen Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 230000003579 anti-obesity Effects 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 150000004283 biguanides Chemical class 0.000 claims 2
- 239000003613 bile acid Substances 0.000 claims 2
- 229920000080 bile acid sequestrant Polymers 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229940125542 dual agonist Drugs 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 206010020718 hyperplasia Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 229960003512 nicotinic acid Drugs 0.000 claims 2
- 235000001968 nicotinic acid Nutrition 0.000 claims 2
- 239000011664 nicotinic acid Substances 0.000 claims 2
- 229960004738 nicotinyl alcohol Drugs 0.000 claims 2
- 230000002611 ovarian Effects 0.000 claims 2
- 239000004031 partial agonist Substances 0.000 claims 2
- 239000002530 phenolic antioxidant Substances 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000005493 quinolyl group Chemical group 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 150000003536 tetrazoles Chemical class 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- STWITCBWQHTJFJ-XMMPIXPASA-N (2r)-2-[3-[3-(4-methoxybenzoyl)-2-methyl-6-(trifluoromethoxy)indol-1-yl]phenoxy]butanoic acid Chemical compound CC[C@H](C(O)=O)OC1=CC=CC(N2C3=CC(OC(F)(F)F)=CC=C3C(C(=O)C=3C=CC(OC)=CC=3)=C2C)=C1 STWITCBWQHTJFJ-XMMPIXPASA-N 0.000 claims 1
- QTNLJMSTDKBAOB-XMMPIXPASA-N (2r)-2-[3-[[3-(4-chlorobenzoyl)-2-methyl-6-(trifluoromethoxy)indol-1-yl]methyl]phenoxy]butanoic acid Chemical compound CC[C@H](C(O)=O)OC1=CC=CC(CN2C3=CC(OC(F)(F)F)=CC=C3C(C(=O)C=3C=CC(Cl)=CC=3)=C2C)=C1 QTNLJMSTDKBAOB-XMMPIXPASA-N 0.000 claims 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 1
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 1
- KTZNLSNSBFSGOQ-UHFFFAOYSA-N 2-[6-[3-(4-methoxybenzoyl)-2-methyl-6-(trifluoromethoxy)indol-1-yl]pyridin-2-yl]oxy-2-methylpropanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)C(C1=CC=C(OC(F)(F)F)C=C11)=C(C)N1C1=CC=CC(OC(C)(C)C(O)=O)=N1 KTZNLSNSBFSGOQ-UHFFFAOYSA-N 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40674102P | 2002-08-29 | 2002-08-29 | |
| US44067203P | 2003-01-17 | 2003-01-17 | |
| PCT/US2003/027156 WO2004020409A1 (en) | 2002-08-29 | 2003-08-27 | Indoles having anti-diabetic activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006500384A JP2006500384A (ja) | 2006-01-05 |
| JP2006500384A5 true JP2006500384A5 (enExample) | 2007-01-18 |
| JP4377815B2 JP4377815B2 (ja) | 2009-12-02 |
Family
ID=31981430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004531948A Expired - Fee Related JP4377815B2 (ja) | 2002-08-29 | 2003-08-27 | 抗糖尿病活性を有するインドール類 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7186746B2 (enExample) |
| JP (1) | JP4377815B2 (enExample) |
| KR (1) | KR20050057074A (enExample) |
| CN (1) | CN100457730C (enExample) |
| AU (1) | AU2003265681A1 (enExample) |
| BR (1) | BR0313825A (enExample) |
| CA (1) | CA2495943C (enExample) |
| DE (1) | DE60332125D1 (enExample) |
| DK (1) | DK1537078T3 (enExample) |
| EC (1) | ECSP055632A (enExample) |
| ES (1) | ES2342596T3 (enExample) |
| HR (1) | HRP20050181A2 (enExample) |
| IL (1) | IL166764A0 (enExample) |
| IS (1) | IS7680A (enExample) |
| MA (1) | MA27396A1 (enExample) |
| MX (1) | MXPA05002303A (enExample) |
| NO (1) | NO20051546L (enExample) |
| NZ (1) | NZ538031A (enExample) |
| PL (1) | PL375302A1 (enExample) |
| PT (1) | PT1537078E (enExample) |
| RU (1) | RU2328483C2 (enExample) |
| WO (2) | WO2004020408A1 (enExample) |
Families Citing this family (139)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004019869A2 (en) * | 2002-08-29 | 2004-03-11 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| CA2495943C (en) * | 2002-08-29 | 2009-07-21 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| RS20050532A (sr) | 2003-01-14 | 2007-12-31 | Arena Pharmaceuticals Inc., | Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija |
| AU2004231106A1 (en) * | 2003-04-14 | 2004-10-28 | The Institutes For Pharmaceutical Discovery, Llc | N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes |
| EA200501710A1 (ru) | 2003-04-30 | 2006-06-30 | ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи | Замещённые карбоновые кислоты |
| KR20060056944A (ko) | 2003-07-14 | 2006-05-25 | 아레나 파마슈티칼스, 인크. | 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료 |
| AU2005244770A1 (en) | 2004-04-26 | 2005-12-01 | Vanderbilt University | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity |
| EP1758856A2 (en) * | 2004-05-04 | 2007-03-07 | Novo Nordisk A/S | Indole derivatives for the treatment of obesity |
| US20080076810A1 (en) * | 2004-05-28 | 2008-03-27 | Weiguo Lui | Benzoureas Having Anti-Diabetic Activity |
| EP1758579A1 (en) * | 2004-05-29 | 2007-03-07 | 7TM Pharma A/S | Crth2 receptor ligands for medicinal uses |
| US7625933B2 (en) | 2004-07-02 | 2009-12-01 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| US7423172B2 (en) | 2004-07-30 | 2008-09-09 | Laboratorios Salvat, S.A. | Tyrosine derivatives as PPAR-γ-modulators |
| AU2005311826A1 (en) * | 2004-11-30 | 2006-06-08 | Plexxikon, Inc. | Indole derivatives for use as PPAR active compounds |
| MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| EP1837329A4 (en) * | 2005-01-14 | 2009-08-05 | Dainippon Sumitomo Pharma Co | NEW HETEROARYL DERIVATIVE |
| WO2006077366A1 (en) * | 2005-01-19 | 2006-07-27 | Biolipox Ab | Indoles useful in the treatment of inflammation |
| US7538242B2 (en) | 2005-03-01 | 2009-05-26 | Kowa Co., Ltd. | Optically active PPAR-activating compound intermediate and method for producing same |
| CA2598725C (en) | 2005-03-04 | 2010-10-26 | Merck & Co., Inc. | Fused aromatic compounds having anti-diabetic activity |
| US7683092B2 (en) | 2005-03-10 | 2010-03-23 | Merck Sharp & Dohme Corp. | Crystalline forms of antidiabetic compounds |
| MX2008003202A (es) * | 2005-09-16 | 2008-03-25 | Serenex Inc | Derivados de carbazol. |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| CA2657691A1 (en) | 2006-06-19 | 2007-12-27 | Vanderbilt University | Methods and compositions for diagnostic and therapeutic targeting of cox-2 |
| TW200821284A (en) * | 2006-10-03 | 2008-05-16 | Merck & Co Inc | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| US8168815B2 (en) | 2007-01-26 | 2012-05-01 | Kaneq Pharma Inc. | Fused aromatic PTP-1B inhibitors |
| PE20090159A1 (es) | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
| EP2155187B1 (en) | 2007-05-07 | 2016-05-25 | Merck Sharp & Dohme Corp. | Method of treatment using fused aromatic compounds having anti-diabetic activity |
| RU2361581C2 (ru) * | 2007-09-14 | 2009-07-20 | Закрытое Акционерное Общество "Мастерклон" | Фармацевтическая композиция, обладающая противодиабетической, гиполипидемической, гипогликемической и гипохолестеринемической активностью, способ ее получения и способы лечения указанных заболеваний |
| TW200920369A (en) | 2007-10-26 | 2009-05-16 | Amira Pharmaceuticals Inc | 5-lipoxygenase activating protein (flap) inhibitor |
| JP5791500B2 (ja) | 2008-05-23 | 2015-10-07 | パンミラ ファーマシューティカルズ，エルエルシー． | ５−リポキシゲナーゼ活性化タンパク質阻害剤 |
| WO2010001869A1 (ja) * | 2008-06-30 | 2010-01-07 | 武田薬品工業株式会社 | ４置換ベンゼン化合物およびその用途 |
| TWI494123B (zh) * | 2008-08-11 | 2015-08-01 | Mannkind Corp | 超快起作用胰島素之用途 |
| US8546431B2 (en) | 2008-10-01 | 2013-10-01 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
| JP5514831B2 (ja) | 2008-11-17 | 2014-06-04 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病の治療のための置換二環式アミン |
| RU2408579C2 (ru) * | 2008-12-31 | 2011-01-10 | Федеральное государственное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" (ЮФУ) | Гидрогалогениды n-[2-(1-алкил-1н-индол-3-ил)-1-(4-алкилпиперазин-1-карбонил)винил]-2-фторбензамида, обладающие местноанестезирующей и антиаритмической активностью |
| TW201028414A (en) | 2009-01-16 | 2010-08-01 | Merck Sharp & Dohme | Oxadiazole beta carboline derivatives as antidiabetic compounds |
| WO2010085528A1 (en) | 2009-01-23 | 2010-07-29 | Schering Corporation | Bridged and fused antidiabetic compounds |
| EP2389226B1 (en) | 2009-01-23 | 2013-11-20 | Merck Sharp & Dohme Corp. | Bridged and fused heterocyclic antidiabetic compounds |
| EP2393810A1 (en) | 2009-02-05 | 2011-12-14 | Schering Corporation | Phthalazine-containing antidiabetic compounds |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| CA2768577A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| WO2011019538A1 (en) | 2009-08-13 | 2011-02-17 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| IN2012DN00721A (enExample) | 2009-09-02 | 2015-06-19 | Merck Sharp & Dohme | |
| EP2523558A4 (en) | 2010-01-15 | 2013-06-19 | Merck Sharp & Dohme | OXADIAZOL BETA CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS |
| KR20120117905A (ko) | 2010-01-28 | 2012-10-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 프로테아좀 활성을 향상시키는 조성물 및 방법 |
| EP2538783B1 (en) | 2010-02-22 | 2016-06-01 | Merck Sharp & Dohme Corp. | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| JP2013100235A (ja) * | 2010-03-08 | 2013-05-23 | Dainippon Sumitomo Pharma Co Ltd | 新規インドール誘導体 |
| US8785634B2 (en) | 2010-04-26 | 2014-07-22 | Merck Sharp & Dohme Corp | Spiropiperidine prolylcarboxypeptidase inhibitors |
| WO2011143057A1 (en) | 2010-05-11 | 2011-11-17 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
| WO2011146358A1 (en) | 2010-05-21 | 2011-11-24 | Merck Sharp & Dohme Corp. | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| EP2579873A4 (en) | 2010-06-11 | 2013-11-27 | Merck Sharp & Dohme | NOVEL PROLYLCARBOXYPEPTIDASE HEMMER |
| US8742110B2 (en) | 2010-08-18 | 2014-06-03 | Merck Sharp & Dohme Corp. | Spiroxazolidinone compounds |
| EP2606031B1 (en) | 2010-08-20 | 2017-09-27 | Amira Pharmaceuticals, Inc. | Autotaxin inhibitors and uses thereof |
| CN103221410B (zh) | 2010-09-22 | 2017-09-15 | 艾尼纳制药公司 | Gpr119受体调节剂和对与其相关的障碍的治疗 |
| AU2011320595A1 (en) | 2010-10-29 | 2013-06-06 | Merck Sharp & Dohme Corp. | Diazeniumdiolate heterocyclic derivatives |
| RU2598842C2 (ru) | 2011-01-20 | 2016-09-27 | Мерк Шарп Энд Домэ Корп. | Антагонисты рецептора минералокортикоидов |
| JO3350B1 (ar) | 2011-03-07 | 2019-03-13 | Merck Sharp & Dohme | مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات |
| US8957062B2 (en) | 2011-04-08 | 2015-02-17 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| EP2697203B1 (en) | 2011-04-13 | 2017-05-24 | Merck Sharp & Dohme Corporation | Mineralocorticoid receptor antagonists |
| WO2012151114A1 (en) | 2011-05-02 | 2012-11-08 | Merck Sharp & Dohme Corp. | Diazeniumdiolate cyclohexyl derivatives |
| TR201906779T4 (tr) * | 2011-05-12 | 2019-05-21 | Proteostasis Therapeutics Inc | Proteostaz regülatörleri. |
| US9260416B2 (en) | 2011-05-27 | 2016-02-16 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
| WO2012164071A1 (en) | 2011-06-02 | 2012-12-06 | Intervet International B.V. | Imidazole derivatives |
| EP2720544B1 (en) | 2011-06-16 | 2016-12-21 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment |
| WO2013048916A1 (en) | 2011-09-30 | 2013-04-04 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| WO2013055606A1 (en) | 2011-10-13 | 2013-04-18 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
| US9346803B2 (en) | 2011-10-17 | 2016-05-24 | Vanderbilt University | Indomethacin analogs for the treatment of castrate-resistant prostate cancer |
| EP2771000B1 (en) | 2011-10-24 | 2016-05-04 | Merck Sharp & Dohme Corp. | Substituted piperidinyl compounds useful as gpr119 agonists |
| JO3210B1 (ar) | 2011-10-28 | 2018-03-08 | Merck Sharp & Dohme | مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة |
| WO2013068328A1 (en) | 2011-11-07 | 2013-05-16 | Intervet International B.V. | Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors |
| WO2013068439A1 (en) | 2011-11-09 | 2013-05-16 | Intervet International B.V. | 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors |
| CA2855009C (en) | 2011-11-15 | 2019-07-09 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as gpr119 agonists |
| EP2814485A4 (en) | 2012-02-17 | 2015-08-26 | Merck Sharp & Dohme | DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES |
| WO2013150534A1 (en) * | 2012-04-03 | 2013-10-10 | Aposense Ltd. | Novel targeting agents for diagnostic and therapeutic indications |
| CA2870488A1 (en) | 2012-04-16 | 2013-10-24 | Kaneq Pharma Inc. | Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors |
| EP2874622A4 (en) | 2012-07-23 | 2015-12-30 | Merck Sharp & Dohme | TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS |
| EP2931734B1 (en) | 2012-12-17 | 2020-12-02 | Merck Sharp & Dohme Corp. | Novel glucokinase activator compounds, compositions containing such compounds, and methods of treatment |
| EP2934518B1 (en) | 2012-12-19 | 2020-02-19 | Merck Sharp & Dohme Corp. | Spirocyclic cetp inhibitors |
| WO2014116228A1 (en) | 2013-01-25 | 2014-07-31 | President And Fellows Of Harvard College | Usp14 inhibitors for treating or preventing viral infections |
| EP3046909A4 (en) | 2013-09-17 | 2017-03-29 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
| US9714240B2 (en) | 2013-09-17 | 2017-07-25 | Pharmakea, Inc. | Vinyl autotaxin inhibitor compounds |
| US9850203B2 (en) | 2013-09-26 | 2017-12-26 | Pharmakea, Inc. | Autotaxin inhibitor compounds |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| PE20160654A1 (es) | 2013-11-22 | 2016-07-15 | Pharmakea Inc | Compuestos de inhibidor de autotaxina |
| WO2015089809A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
| US10065945B2 (en) | 2014-01-24 | 2018-09-04 | Merck Sharp & Dohme Corp. | Isoquinoline derivatives as MGAT2 inhibitors |
| JP6572414B2 (ja) * | 2014-05-20 | 2019-09-11 | ラクオリア創薬株式会社 | ベンズイソオキサゾール誘導体塩 |
| WO2015176267A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP3174537B1 (en) | 2014-07-29 | 2021-06-23 | Merck Sharp & Dohme Corp. | Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein |
| US10100042B2 (en) | 2014-08-08 | 2018-10-16 | Merck Sharp & Dohme Corp. | [5,6]—fused bicyclic antidiabetic compounds |
| WO2016022448A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2016022742A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| JP6581656B2 (ja) | 2014-10-24 | 2019-09-25 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | グルカゴンおよびｇｌｐ−１受容体のコアゴニスト |
| TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
| CA3002540C (en) | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
| US10245264B2 (en) | 2015-05-27 | 2019-04-02 | Merck Sharp & Dohme Corp. | Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators |
| CN116059203A (zh) | 2015-05-27 | 2023-05-05 | 赛博治疗有限责任公司 | 自分泌运动因子抑制剂及其用途 |
| EP3310782B1 (en) | 2015-05-28 | 2021-12-01 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
| JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩 |
| WO2017011279A1 (en) | 2015-07-13 | 2017-01-19 | Merck Sharp & Dohme Corp. | Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein |
| US10800826B2 (en) | 2015-10-05 | 2020-10-13 | Merck Sharp & Dohme Corp. | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors |
| AU2016333963C1 (en) * | 2015-10-07 | 2021-05-27 | The Salk Institute For Biological Studies | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| WO2017095725A1 (en) | 2015-11-30 | 2017-06-08 | Merck Sharp & Dohme Corp. | Aryl sulfonamides as blt1 antagonists |
| WO2017095724A1 (en) | 2015-11-30 | 2017-06-08 | Merck Sharp & Dohme Corp. | Aryl sulfonamides as blt1 antagonists |
| WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
| CN107286158A (zh) * | 2016-03-30 | 2017-10-24 | 中国科学院上海药物研究所 | 苯基[a]吲哚[2,3-g]并喹嗪类化合物、其制备方法、药物组合物及其应用 |
| US11358954B2 (en) | 2016-04-13 | 2022-06-14 | Mitobridge, Inc. | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
| WO2017201683A1 (en) | 2016-05-25 | 2017-11-30 | Merck Sharp & Dohme Corp. | Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists |
| US10414774B2 (en) | 2016-08-15 | 2019-09-17 | Merck Sharp & Dohme Corp. | Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease |
| US10414775B2 (en) | 2016-08-15 | 2019-09-17 | Merck Sharp & Dohme Corp. | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease |
| EP3515891B1 (en) | 2016-09-20 | 2023-03-08 | Merck Sharp & Dohme LLC | Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as pcsk9 allosteric binders |
| CN109963561A (zh) | 2016-11-18 | 2019-07-02 | 默沙东公司 | 可用作二酰基甘油酯o-酰基转移酶2的抑制剂的吲哚衍生物 |
| RU2019117556A (ru) | 2016-11-18 | 2020-12-18 | Мерк Шарп И Доум Корп. | Индазольные производные, пригодные в качестве ингибиторов диацилглицерид o-ацилтрансферазы 2 |
| WO2018107415A1 (en) | 2016-12-15 | 2018-06-21 | Merck Sharp & Dohme Corp. | Hydroxy isoxazole compounds useful as gpr120 agonists |
| CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
| JP7397011B2 (ja) | 2018-06-06 | 2023-12-12 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１ｐ１受容体に関連する状態を治療する方法 |
| KR20250161677A (ko) | 2018-06-21 | 2025-11-17 | 머크 샤프 앤드 돔 엘엘씨 | Pcsk9 길항제 화합물 |
| US12281109B2 (en) | 2019-04-04 | 2025-04-22 | Merck Sharp & Dohme Llc | Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes |
| WO2020236688A1 (en) | 2019-05-22 | 2020-11-26 | Merck Sharp & Dohme Corp. | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes |
| US20220281886A1 (en) | 2019-05-22 | 2022-09-08 | Merck Sharp Dohme Corp. | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes |
| EP4021919A1 (en) | 2019-08-30 | 2022-07-06 | Merck Sharp & Dohme Corp. | Pcsk9 antagonist compounds |
| EP3842060A1 (en) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled lactam co-agonists of the glucagon and glp-1 receptors |
| EP3842449A1 (en) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled olefin co-agonists of the glucagon and glp-1 receptors |
| EP3842061A1 (en) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled triazole co-agonists of the glucagon and glp-1 receptors |
| TWI894229B (zh) | 2020-03-16 | 2025-08-21 | 瑞士商諾華公司 | 作為yap/taz-tead蛋白-蛋白相互作用抑制劑之聯芳基衍生物 |
| US20230174521A1 (en) | 2020-05-18 | 2023-06-08 | Merck Sharp & Dohme Llc | Novel diacylglyceride o-acyltransferase 2 inhibitors |
| KR102993831B1 (ko) | 2020-10-08 | 2026-07-23 | 머크 샤프 앤드 돔 엘엘씨 | 신규 디아실글리세리드 o-아실트랜스퍼라제 2 억제제로서의 옥스인돌 유도체의 제조 |
| MX2024002146A (es) | 2021-08-19 | 2024-03-08 | Merck Sharp & Dohme Llc | Compuestos para el tratamiento de afecciones relacionadas con la actividad de pcsk9. |
| SI4540267T1 (sl) | 2022-06-15 | 2026-07-31 | Merck Sharp & Dohme Llc | Ciklični peptidi za ujetje interlevkina-1 beta |
| AU2023400409A1 (en) | 2022-12-02 | 2025-06-26 | Merck Sharp & Dohme Llc | Preparation of fused azole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors |
| CN121816339A (zh) * | 2023-09-19 | 2026-04-07 | 广东横琴新创益生物医药有限公司 | 一种六元并五元稠环衍生物及其制备方法和应用 |
| IL328311A (en) | 2023-11-14 | 2026-07-01 | Merck Sharp & Dohme Llc | Cyclic peptide for capturing Interleukin-1 Beta |
| AU2024401721A1 (en) | 2023-12-15 | 2026-07-16 | Merck Sharp & Dohme Llc | A cyclic peptide il-1beta trap for the treatment of atherosclerosis and inflammatory disorders |
| US20260022125A1 (en) | 2024-07-19 | 2026-01-22 | Merck Sharp & Dohme Llc | Pyrrolopyridazine vegfr inhibitors |
| WO2026096330A1 (en) | 2024-10-28 | 2026-05-07 | Merck Sharp & Dohme Llc | Glp-1 receptor agonists and methods of use |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5686481A (en) * | 1993-12-21 | 1997-11-11 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| US5482960A (en) * | 1994-11-14 | 1996-01-09 | Warner-Lambert Company | Nonpeptide endothelin antagonists |
| US6297269B1 (en) * | 1995-06-06 | 2001-10-02 | Pfizer Inc. | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
| JP2000516958A (ja) | 1996-08-26 | 2000-12-19 | ジェネティックス・インスチチュート・インコーポレーテッド | ホスホリパーゼ酵素の阻害剤 |
| EE200000522A (et) | 1998-02-25 | 2002-02-15 | Genetics Institute, Inc. | Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks |
| GEP20032920B (en) | 1998-02-25 | 2003-03-25 | Genetics Inst | Inhibitors of Phospholipase Enzymes |
| ID27280A (id) | 1998-02-25 | 2001-03-22 | Genetics Inst | Inhibitor-inhibitor dari enzim-enzim fosfolipase |
| AP2000001929A0 (en) * | 1998-03-31 | 2000-09-30 | Inst For Pharm Discovery Inc | Substituted indolealkanoic acids. |
| GB2362173B (en) * | 1998-11-10 | 2003-05-28 | Baker Hughes Inc | Self-controlled directional drilling systems and methods |
| HUP0104987A3 (en) | 1998-12-18 | 2002-09-30 | Axys Pharmaceuticals Inc South | Benzimidazole or indole derivatives protease inhibitors, and pharmaceutical compositions containing them |
| CA2386750A1 (en) * | 1999-10-22 | 2001-05-03 | Merck & Co. Inc. | Pharmaceuticals for treating obesity |
| CA2415742A1 (en) * | 2000-07-25 | 2002-01-31 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
| IL154981A0 (en) | 2000-10-10 | 2003-10-31 | Smithkline Beecham Corp | Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppay-y-binding agents |
| US6706751B2 (en) * | 2000-12-21 | 2004-03-16 | Hoffman-La Roche Inc. | Dihydroindole and tetrahydroquinoline derivatives |
| EP1424325A4 (en) | 2001-09-07 | 2005-12-21 | Ono Pharmaceutical Co | INDOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE AGENT |
| GB0205165D0 (en) * | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| JP2005532280A (ja) * | 2002-04-03 | 2005-10-27 | アストラゼネカ アクチボラグ | 化合物 |
| US20040038958A1 (en) | 2002-07-11 | 2004-02-26 | Chris Rundfeldt | Topical treatment of skin diseases |
| CA2495943C (en) * | 2002-08-29 | 2009-07-21 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| US7129264B2 (en) * | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| WO2005012243A2 (en) * | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica N.V. | Substituted indole-o-glucosides |
-
2003
- 2003-08-27 CA CA002495943A patent/CA2495943C/en not_active Expired - Fee Related
- 2003-08-27 PL PL03375302A patent/PL375302A1/xx not_active Application Discontinuation
- 2003-08-27 ES ES03791952T patent/ES2342596T3/es not_active Expired - Lifetime
- 2003-08-27 HR HR20050181A patent/HRP20050181A2/hr not_active Application Discontinuation
- 2003-08-27 WO PCT/US2003/026677 patent/WO2004020408A1/en not_active Ceased
- 2003-08-27 AU AU2003265681A patent/AU2003265681A1/en not_active Abandoned
- 2003-08-27 DK DK03791952.9T patent/DK1537078T3/da active
- 2003-08-27 DE DE60332125T patent/DE60332125D1/de not_active Expired - Lifetime
- 2003-08-27 RU RU2005108668/04A patent/RU2328483C2/ru not_active IP Right Cessation
- 2003-08-27 KR KR1020057003552A patent/KR20050057074A/ko not_active Abandoned
- 2003-08-27 PT PT03791952T patent/PT1537078E/pt unknown
- 2003-08-27 JP JP2004531948A patent/JP4377815B2/ja not_active Expired - Fee Related
- 2003-08-27 WO PCT/US2003/027156 patent/WO2004020409A1/en not_active Ceased
- 2003-08-27 US US10/524,697 patent/US7186746B2/en not_active Expired - Lifetime
- 2003-08-27 BR BR0313825-9A patent/BR0313825A/pt not_active IP Right Cessation
- 2003-08-27 NZ NZ538031A patent/NZ538031A/en unknown
- 2003-08-27 MX MXPA05002303A patent/MXPA05002303A/es active IP Right Grant
- 2003-08-27 CN CNB038206919A patent/CN100457730C/zh not_active Expired - Fee Related
-
2005
- 2005-01-31 IS IS7680A patent/IS7680A/is unknown
- 2005-02-08 IL IL16676405A patent/IL166764A0/xx not_active IP Right Cessation
- 2005-02-25 EC EC2005005632A patent/ECSP055632A/es unknown
- 2005-03-16 MA MA28147A patent/MA27396A1/fr unknown
- 2005-03-23 NO NO20051546A patent/NO20051546L/no not_active Application Discontinuation
-
2007
- 2007-03-06 US US11/714,341 patent/US7345085B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003523336A5 (enExample) | ||
| JP2004513076A5 (enExample) | ||
| JP2005502600A5 (enExample) | ||
| JP2009537524A5 (enExample) | ||
| JP2009522292A5 (enExample) | ||
| US11013722B2 (en) | Therapeutic agent for dyslipidemia | |
| JP2007502264A5 (enExample) | ||
| CN1750758B (zh) | 用于治疗代谢紊乱的化合物 | |
| AU2003256911B2 (en) | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | |
| JP2010529203A5 (enExample) | ||
| JP2005509590A5 (enExample) | ||
| Shi et al. | Design and synthesis of α-aryloxyphenylacetic acid derivatives: a novel class of PPARα/γ dual agonists with potent antihyperglycemic and lipid modulating activity | |
| JP2007502263A5 (enExample) | ||
| JP2004534733A5 (enExample) | ||
| JP6054368B2 (ja) | 代謝性疾患治療用ｏ−フルオロ置換化合物またはその塩 | |
| JP2023516235A5 (enExample) | ||
| JP2004517100A5 (enExample) | ||
| JP2006524252A5 (enExample) | ||
| CN1159305C (zh) | 新的2-(n-氰基亚氨基)噻唑烷-4-酮衍生物 | |
| RU2005114373A (ru) | Хиральные производные оксазоларилпропионовой кислоты и их применение в качестве агонистов рецепторов, активированных пролифератором пароксисомы (ppar агонистов) | |
| JP2009528997A5 (enExample) | ||
| CN101993403B (zh) | 氮杂环丁酮类化合物及医药应用 | |
| JPWO2001036402A1 (ja) | 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体 | |
| CA2598725A1 (en) | Fused aromatic compounds having anti-diabetic activity | |
| US10442761B2 (en) | Deuterated GFT-505 |